Drugs / NeisVac-C
NeisVac-C
Trials 12 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00631995 | Apr 2008 → Feb 2009 | meningitis, meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 38 trials | ||||||
| Phase 3 | NCT01839188 | May 2013 → Mar 2014 | meningococcal infection, viral infectious disease | MCM Vaccines B.V. | Completed | No outcome recorded |
| Phase 3 | NCT01839175 | Apr 2013 → Jul 2014 | meningococcal infection, viral infectious disease | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT01553279 | Mar 2012 → Sep 2013 | meningococcal infection, viral infectious disease | MCM Vaccines B.V. | Completed | No outcome recorded |
| Phase 3 | NCT01218451 | Sep 2010 → Jan 2012 | meningococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00463437 | Apr 2007 → Jan 2008 | diphtheria, hepatitis B virus infection, pneumococcal infection, poliomyelitis +1 | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00443846 | Feb → Sep 2007 | Rotavirus infection, meningococcal meningitis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00384059 | Oct 2006 → Oct 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00161928 | Apr 2002 → Jan 2003 | meningococcal meningitis | Pfizer | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT02002156 | Jun 2014 → Aug 2016 | tuberculosis | University of Oxford | Completed | No outcome recorded |
| Phase 4 | NCT00936962 | Jul 2009 → Jun 2015 | meningococcal infection | University of British Columbia | Completed | No outcome recorded |
| Phase 4 | NCT00625677 | Feb 2008 → Mar 2010 | meningococcal infection, pneumococcal infection | Public Health England | Completed | No outcome recorded |
Also used as a comparator or background therapy in 7 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01171989 Comparator | Aug → Dec 2010 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, poliomyelitis +1 | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT03890367 Comparator | Sep 2019 → Oct 2020 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT03932682 Comparator | May 2019 → Nov 2023 | influenza | Seqirus | Completed | No outcome recorded |
| Phase 3 | NCT00322335 Comparator | May → Jul 2006 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00327184 Comparator | Apr → Nov 2006 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT02526394 Comparator | Sep 2013 → Mar 2017 | meningococcal meningitis, pertussis | Public Health England | Completed | No outcome recorded |
| Phase 4 | NCT01896596 Comparator | Jul 2013 → Apr 2017 | haemophilus infectious disease, hepatitis B virus infection, meningococcal infection, pneumococcal infection | Public Health England | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NeisVac-C | “Study of NeisVac-C Vaccine to Evaluate Immunological Interference With Hepatitis B, Inactivated Polio and Acellular Pertussis Vaccines in Healthy Infants” NCT00161928 ↗19“Subjects receive 2 primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age of NeisVac-C™ + Infanrix™ hexa vaccines.” NCT00327184 ↗ “A Phase 3b, Randomized, Open Label, Feasibility Study of a Single Priming Dose of Meningococcal Group C Conjugate Vaccine (NeisVac-C) in Infants” NCT01218451 ↗ “Following the first dose of NeisVac-C (MCC conjugated to tetanus toxoid), 97% of infants achieved protective levels” PMID 19091990 ↗ Dec 2008 “Meningococcal Group C Polysaccharide Conjugate Vaccine (NeisVac-C)” NCT03932682 ↗ “received a single dose of NeisVac-C® vaccine on Day 0.” NCT03890367 ↗ “Meningitec, NeisVacC, Menitorix, Menveo, Nimenrix” NCT02526394 ↗ “A single dose of NeisVac-C® vaccine.” NCT00631995 ↗ |
| Known as | MCC-TT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01553279 ↗ |
| Known as | NeisVac C vaccine (Baxter) | “NeisVac C vaccine (Baxter)” NCT00936962 ↗ |
| Known as | NeisVac---C, Baxter Healthcare Ltd. | “NeisVac---C®, Baxter Healthcare Ltd.” NCT02002156 ↗ |
| Modality | Vaccine | “NeisVac-C Vaccine” NCT00161928 ↗ |
| Route | Intramuscular | “0.5 mL suspension for intramuscular injection” NCT00443846 ↗ |